MCPHS / Takeda - Global Medical Communications Oncology (2 years) - Post PharmD Fellow
Location: Cambridge, Massachusetts
Specialty Practice Areas:
The fellow will receive a competitive stipend and benefits package, including comprehensive health and dental insurance. Attendance at one or more professional meetings, conferences, or workshops will be sponsored by the fellowship program. The fellow may qualify for student loan deferment, allowing for the postponement of loan payments until the completion of the fellowship program. The lender of the student loan(s) will be able to provide specific information regarding eligibility and terms of deferment.
Employer will assist with relocation costs.
The Global Medical Communications Oncology Fellowship is a 2 year program designed to provide fellows with in-depth experience that will help them develop the core competencies in Medical Communications as well as understand its value across broader functions in the pharmaceutical industry. During the first year of the fellowship, the fellow will complete 3 rotations. The first 2 rotations will be in medical communications functions (publications, disease/training, and congresses/outreach/medical education). The 3rd rotation may be within a medical communications function or with other functions that partner with medical communications, this rotation will be based on fellow's interest, business need, and rotation availability. The 2nd year of the fellowship will be an immersive experience with the global medical communication leads.
Global Medical Communications Oncology is responsible for strategically developing and driving the communication of scientific data in a consistent, meaningful, accurate, and balanced manner with "One Scientific Voice."
In this role the fellow will have the opportunity to:
Support implementation of medical strategy and tactical plans by contributing to creation of medical communication materials such as publications, scientific platforms, scientific narratives, MSL slide decks, training, FAQs, and congress symposia
Assist in the medical/scientific review of global/regional oncology materials
Collaborate with the core medical team on the development of advisory board meetings
Expand medical knowledge of oncology products and understand how medical communication strategy is adapted with different stages of a drug's life cycle, extending from pipeline to marketed stage
Train with the centers of excellence (publications, disease/product training, and congresses/outreach/medical education teams) and the medical communication leads to obtain a strong understanding of how the different functions within medical communications work together to deliver on our medical goals
To be considered for an interview, please complete a fellowship application on the MCPHS SMApply application portal. Visit https://mcphs.smapply.io/
Please DO NOT request an interview within PPS. Our recruitment teams will contact qualified candidates via email to schedule interviews.
The MCPHS application portal will open on October 3, 2022. Applicants must upload the following application materials to the online portal by November 11, 2022:
Letter of intent
Unofficial college transcript
Contact information for three references. References will receive an electronic recommendation form to complete separately.
Incomplete applications WILL NOT be reviewed. Interviews CANNOT be scheduled until these materials have been submitted. Please keep in mind that this is a competitive process and applicants are encouraged to complete their applications as soon as possible.
Three recommendation evaluation forms must be submitted no later than December 1, 2022, via the online portal. This is NOT a letter of recommendation but an online form that the reference will need to complete.
Rolling Application Review & Interviews
All submitted applications will be reviewed on a rolling basis. Interviews will also be offered on a rolling basis and opportunities are limited. Priority will be given to those applicants who apply early, well in advance of the deadline.
Rolling interviews will begin mid-October with pre-screens and a mixture of interview rounds, and will conclude in December at the end of the ASHP Midyear Clinical Meeting. Candidates will be notified if selected for an interview.
ASHP Midyear & Onsite Interviews
The fellowship program will be conducting in-person interviews at the ASHP Midyear Clinical Meeting in Las Vegas. Applicants are strongly encouraged to attend. Candidates attending in-person will not be able to interview without registering for both ASHP and PPS. Please refer to the ASHP & PPS website for registration details.
Recognizing that the choice of a postdoctoral industry fellowship is an important decision, MCPHS in conjunction with the Academic Industry Fellowship Alliance (AIFA), has agreed to extend offers for fellowships no earlier than December 7, 2022.
The AIFA is comprised of Keck Graduate Institute (KGI), Massachusetts College of Pharmacy and Health Sciences (MCPHS), Northeastern University Pharmaceutical Industry Fellowships, Purdue University College of Pharmacy, Rutgers Institute for Pharmaceutical Industry Fellowships (RPIF), Saint Joseph’s University, University of North Carolina Division of Pharmacotherapy and Experimental Therapeutics (UNC, DPET), and University of Southern California School of Pharmacy (USC School of Pharmacy).
We see this respect for candidate choice as a common aspect of each of our program’s cultures. We hope that other academic and non-academic fellowship programs will respect this timeline.
Final candidates will be required to go through additional screening/onboarding as required by MCPHS.
The MCPHS Biopharmaceutical Industry fellows will be selected on a nationally competitive basis. Applicants must have a Doctor of Pharmacy degree from an ACPE-accredited college of pharmacy at the commencement of the program.
Candidates must have strong written and verbal communication skills and a strong interest in pursuing a career within the biopharmaceutical industry.
All candidates must have authorization to work in the United States throughout the duration of the one or two year fellowship. No visa sponsorship will be provided (i.e., TN, H-1B, STEM OPT, etc.).
Founded in 1781, Takeda is a patient-focused, values-based, research and development (R&D)-driven global biopharmaceutical company committed to bringing Better Health and a Brighter Future to people worldwide. Our passion and pursuit of potentially life-changing treatments for patients are deeply rooted in our distinguished 240-year history in Japan. At the U.S. headquarters for Takeda, four of our eight global business units and biologics manufacturing site are centered in Massachusetts enabling us to build relationships with cutting-edge companies, academic institutions, scientists and organizations who join us in the effort to discover, develop, and deliver new treatments to patients. We have 20 locations across the greater Boston area. As a R&D-driven organization, Takeda has state-of-the-art facilities to help advance the next generation of innovation. Takeda’s pharmaceutical products are marketed in around 100 countries worldwide, including partnerships (marketing alliance partners). The company has grown in size and scope both organically and through acquisition. Takeda-ism (our values of Integrity, Fairness, Honesty, and Perseverance) grounds us as we deliver on our role to... serve the public by ensuring integrity in our every action for and on behalf of patients.
Takeda focuses its R&D efforts on four therapeutic areas: oncology, gastroenterology (GI), rare diseases and neuroscience. We also make targeted R&D investments in plasma-derived therapies and vaccines. For more than 70 years, Takeda has supplied vaccines to protect the health of people in Japan. Today, Takeda’s global vaccine business is applying innovation to tackle some of the world’s most challenging infectious diseases, such as dengue, Zika and norovirus. We are developing highly innovative medicines that contribute to making a difference in people’s lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline.